Table 2.
Pre-hospital, periprocedural and discharge medications, agiographic findings, and procedural results of the study patients stratified by the primary endpoint
| Variable | No such events n = 588 |
Primary endpoint n = 188 |
P value |
|---|---|---|---|
| Medications before admission | |||
| Aspirin, n (%) | 432 (73.5) | 146 (77.7) | 0.251 |
| P2Y12 inhibitors, n (%) | 231 (39.3) | 79 (42.0) | 0.505 |
| Lipid-lowering drugs, n (%) | 430 (73.1) | 144 (76.6) | 0.346 |
| ACEI/ARBs, n (%) | 180 (30.6) | 74 (39.4) | 0.026 |
| β-blockers, n (%) | 227 (38.6) | 71 (37.8) | 0.837 |
| Insulin, n (%) | 209 (35.5) | 73 (38.8) | 0.415 |
| Oral antidiabetic agents, n (%) | 284 (48.3) | 92 (48.9) | 0.879 |
| Metformin, n (%) | 144 (24.5) | 44 (23.4) | 0.762 |
| Alpha-glucosidase inhibitors, n (%) | 123 (20.9) | 31 (16.5) | 0.185 |
| Sulfonylurea, n (%) | 135 (23.0) | 43 (22.9) | 0.980 |
| Dipeptidyl peptidase 4 inhibitors, n (%) | 8 (1.4) | 4 (2.1) | 0.687 |
| Any antidiabetic treatment, n (%) | 419 (71.3) | 143 (76.1) | 0.199 |
| Periprocedural medications | |||
| Aspirin, n (%) | 588 (100.0) | 182 (96.8) | < 0.001 |
| P2Y12 inhibitors, n (%) | 588 (100.0) | 188 (100.0) | – |
| Unfractionated heparin, n (%) | 482 (82.0) | 156 (83.0) | 0.754 |
| Bivalirudin, n (%) | 77 (13.1) | 23 (12.2) | 0.759 |
| GP IIb/IIIa receptor antagonist, n (%) | 100 (17.0) | 42 (22.3) | 0.100 |
| Medications at discharge | |||
| Aspirin, n (%) | 588 (100.0) | 182 (96.8) | < 0.001 |
| P2Y12 inhibitors, n (%) | 588 (100.0) | 188 (100.0) | – |
| Lipid-lowering drugs, n (%) | 588 (100.0) | 188 (100.0) | – |
| ACEI/ARBs, n (%) | 283 (48.1) | 99 (52.7) | 0.279 |
| β-blockers, n (%) | 432 (73.5) | 130 (69.1) | 0.249 |
| Insulin, n (%) | 188 (32.0) | 76 (40.4) | 0.033 |
| Oral antidiabetic agents, n (%) | 318 (54.1) | 100 (53.2) | 0.831 |
| Metformin, n (%) | 90 (15.3) | 32 (17.0) | 0.574 |
| Alpha-glucosidase inhibitors, n (%) | 214 (36.4) | 64 (34.0) | 0.558 |
| Sulfonylurea, n (%) | 146 (24.8) | 42 (22.3) | 0.488 |
| Dipeptidyl peptidase 4 inhibitors, n (%) | 8 (1.4) | 4 (1.2) | 0.687 |
| Any antidiabetic treatment, n (%) | 408 (69.4) | 150 (79.8) | 0.006 |
| Angiographic findings | |||
| One-vessel disease, n (%) | 68 (11.6) | 6 (3.2) | 0.001 |
| Two-vessel disease, n (%) | 164 (27.9) | 30 (16.0) | 0.001 |
| LM/three-vessel disease, n (%) | 356 (60.5) | 152 (80.9) | < 0.001 |
| Proximal LAD stenosis, n (%) | 291 (49.5) | 103 (54.8) | 0.206 |
| Restenotic lesions, n (%) | 61 (10.4) | 49 (26.1) | < 0.001 |
| Chronic total occlusions, n (%) | 136 (23.1) | 40 (21.3) | 0.597 |
| Trifurcation or bifurcation lesions, n (%) | 450 (76.5) | 148 (78.7) | 0.534 |
| Heavy calcification lesions, n (%) | 193 (32.8) | 65 (34.6) | 0.657 |
| Lesions > 20 mm long, n (%) | 312 (53.1) | 134 (71.3) | < 0.001 |
| Procedural results | |||
| Target vessel territory | |||
| LM, n (%) | 30 (5.1) | 12 (6.4) | 0.499 |
| LAD, n (%) | 291 (49.5) | 91 (48.4) | 0.796 |
| LCX, n (%) | 168 (28.6) | 52 (27.7) | 0.809 |
| RCA, n (%) | 231 (39.3) | 75 (39.9) | 0.882 |
| DES use, n (%) | 492 (83.7) | 154 (81.9) | 0.574 |
| BRS use, n (%) | 27 (4.6) | 5 (2.7) | 0.246 |
| DCB use, n (%) | 32 (5.4) | 22 (11.7) | 0.003 |
| Complete revascularization, n (%) | 376 (63.9) | 80 (42.6) | < 0.001 |
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, LM left-main artery, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, DES drug-eluting stent, BRS bioresorbable scaffold, DCB drug-coated balloon